Sign in Subscribe
Diseases

Capstan Therapeutics Announces Successful Dosing of First-In-Human Clinical Trial of CPTX2309, an Investigational In Vivo CAR-T Therapy

Strategic Insights

— 1 min read

Capstan Therapeutics, a clinical-stage biotechnology company, has successfully dosed the first participants in its Phase 1 trial of CPTX2309, a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells. The trial aims to evaluate the safety, tolerability, and pharmacodynamic activity of CPTX2309 in healthy volunteers. This innovative approach is designed to achieve rapid, deep, and transient B cell depletion without the need for chemotherapy, cell manipulation, viral vectors, and DNA integration.

Key Takeaways:

  • CPTX2309 is a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA to CD8-expressing cytotoxic T cells, offering a novel approach to treating B cell-mediated autoimmune disorders.
  • The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of CPTX2309 in healthy volunteers at various dose levels.
  • Preclinical studies demonstrated rapid, deep, and transient B cell depletion in blood and tissues, supporting the clinical evaluation of CPTX2309.
  • The trial's focus on healthy volunteers allows for efficient dose escalation and highlights the potential safety advantages of this approach, which does not involve lymphodepletion or permanent CAR integration into the genome.
  • The goal of the trial is to determine a pharmacologically active dose (or doses) that can be advanced into Phase 2 studies to treat patients with autoimmune disease.
  • Capstan's proprietary CellSeeker TM tLNP platform technology enables targeted in vivo RNA delivery, with potential applications in treating autoimmune diseases.

Statistics:

  • The first participants have been successfully dosed in the Phase 1 trial of CPTX2309.
  • Preclinical studies demonstrated 90% of B cells depleted at the highest dose level.
  • The trial will assess pharmacokinetics and pharmacodynamic activity at various dose levels.
  • The trial is being conducted in Australia.

Sources:

  • "Capstan Therapeutics Announces Successful Dosing of First-In-Human Clinical Trial of CPTX2309, an Investigational In Vivo CAR-T Therapy." Business Wire, 16 June 2025.
  • Capstan Therapeutics, Inc. press release.

Read more